System for determining individual effectiveness of tripterygium glycosides tablets for treating rheumatoid arthritis by expression quantity of plurality of mRNAs

A rheumatoid, expression-level technology, applied in the determination/inspection of microorganisms, bioreactors/fermenters for specific purposes, biochemical instruments, etc. Toxic dose equivalency issues

Active Publication Date: 2018-05-15
INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the large individual differences in clinical efficacy and the equivalent effectiv

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • System for determining individual effectiveness of tripterygium glycosides tablets for treating rheumatoid arthritis by expression quantity of plurality of mRNAs
  • System for determining individual effectiveness of tripterygium glycosides tablets for treating rheumatoid arthritis by expression quantity of plurality of mRNAs
  • System for determining individual effectiveness of tripterygium glycosides tablets for treating rheumatoid arthritis by expression quantity of plurality of mRNAs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] This example is used to illustrate the discovery of biomarkers and the establishment of prediction models of the present disclosure.

[0043] Source of cases and sample size: 40 RA patients who met the inclusion criteria in the rheumatology department and outpatient department of Guang'anmen Hospital, China Academy of Chinese Medical Sciences. At the same time, 10 healthy volunteers from the Health Examination Center were selected, and the age and gender matched the disease group.

[0044] Inclusion criteria: in line with the American College of Rheumatology (American College of Rheumatology, ACR) classification criteria for RA in 1987 and the classification criteria for rheumatoid arthritis in 2010 (ACR / EULAR), never received tripterygium glycosides tablet treatment or in the last 4 days Subjects who have not received the treatment of tripterygium glycosides tablets within a week.

[0045] The classification criteria for rheumatoid arthritis revised by the American Co...

Embodiment 2

[0105] This example serves to illustrate the validation of the disclosed biomarkers and predictive models.

[0106] Reselect 60 cases of RA patients as an independent test set, and the inclusion and exclusion criteria are the same as in Example 1; taking Tripterygium wilfordii polyglycoside tablets for 12 weeks, during which regular follow-ups are performed to detect the indicators of standard treatment, and these RA patients are divided into three groups according to the clinical survey scale: Two groups: standard treatment group and non-standard treatment group; use real-time quantitative PCR (qRT-PCR) to detect the expression levels of MX1, OASL, SPINK1, CRK, GRAPL and RNF2 in the above independent test samples, and further verify the The performance of the curative effect prediction model for individualized treatment of RA, the evaluation indicators include prediction accuracy (accuracy, ACC) receiver operating characteristic curve (receiver operating characteristic curve, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a system for determining the individual effectiveness of tripterygium glycosides tablets for treating rheumatoid arthritis by the expression quantity of a plurality of mRNAs. The plurality of mRNAs comprise MX1, OASL, SPINK1, CRK, GRAPL and RNF2. The invention also provides a molecular marker for determining the individual effectiveness of the tripterygium glycosides tabletsfor treating the rheumatoid arthritis, application thereof in preparing a kit for determining the individual effectiveness of the tripterygium glycosides tablets for treating the rheumatoid arthritisand application of a reagent for detecting the molecular marker in preparing the kit for determining the individual effectiveness of the tripterygium glycosides tablets for treating the rheumatoid arthritis. The technical scheme provided by the invention provides biological marker with high specificity and high sensitivity and a curative-effect prediction model for individual diagnosis and treatment and provides a novel high-efficiency and noninvasive auxiliary tool for clinically making an individualized treatment scheme for the rheumatoid arthritis.

Description

technical field [0001] The present disclosure relates to the field of biomedicine, in particular, to a system for determining the individual effectiveness of tripterygium glycosides tablets in treating rheumatoid arthritis through the expression levels of multiple mRNAs, and a system for determining the effectiveness of tripterygium glycosides tablets in treating rheumatoid arthritis. Molecular markers for the individual effectiveness of rheumatoid arthritis, the use of the molecular markers in the preparation of kits for determining the individual effectiveness of tripterygium glycosides in the treatment of rheumatoid arthritis, and the method for detecting the expression level of the molecular markers The use of the reagent in the preparation of a kit for determining the individual effectiveness of tripterygium glycosides in treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (Rheumatoid arthritis, RA) is a refractory autoimmune disease in the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6883C12M1/34
CPCC12Q1/6883C12Q2600/106C12Q2600/158C12Q2600/16C12Q2600/166
Inventor 张彦琼林娜王海隆
Owner INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap